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Effects of Bacillus Calmette-Guérin 
(BCG) vaccination at birth on T and 
B lymphocyte subsets: Results from 
a clinical randomized trial
Nina Marie Birk  1, Thomas Nørrelykke Nissen  1, Jesper Kjærgaard2, Hans Jacob Hartling3, 
Lisbeth Marianne Thøstesen4, Poul-Erik Kofoed4, Lone Graff Stensballe2, Andreas Andersen5, 
Ole Pryds1, Mihai G. Netea6, Christine Stabell Benn5, Susanne Dam Nielsen3 &  
Dorthe Lisbeth Jeppesen1
The Bacillus Calmette–Guérin vaccine (BCG) has been associated with beneficial non-specific effects 
(NSEs) on infant health. Within a randomized trial on the effect of neonatal BCG on overall health, 
we investigated the possible immunological impact of neonatal BCG vaccination on lymphocyte 
subsets, determined by flow cytometry. In 118 infants blood samples were obtained 4 (±2) days post 
randomization to BCG vaccination or no intervention, and at 3 and 13 months of age. No effects of 
BCG were found at 4 days. However, BCG increased proportions of effector memory cells at 3 months 
(Geometric mean ratio (GMR) 1.62, 95% confidence interval (CI) (1.20–2.21), p = 0.002 for CD4+ T 
cells and GMR 1.69, 95% CI (1.06–2.70), p = 0.03 for CD8+ T cells), and reduced proportions of late 
differentiated CD4+ T cells (GMR = 0.62, 95% CI (0.38–1.00), p = 0.05) and apoptotic CD4+ T cells at 13 
months (GMR = 0.55, 95% CI (0.32–0.92), p = 0.03). In conclusion, limited overall impact of neonatal 
BCG vaccination on lymphocyte subsets was found in healthy Danish infants within the first 13 months 
of life. This is in line with the limited clinical effects of BCG observed in our setting.
The Bacillus Calmette-Guérin vaccine (BCG) used against tuberculosis (TB) has been administered to billions 
of infants and is still one of the most used vaccines worldwide1. The observation that BCG may have beneficial 
non-specific clinical effects (NSEs) beyond the specific protection against TB dates back to the 1930s2, and today 
BCG is used in standard treatment of bladder cancer.
Both observational studies3–6 and recent randomized clinical trials7,8 from low-income countries found that 
neonatal BCG vaccination reduced all-cause morbidity and mortality from infections other than TB. In 2014, 
the Strategic Advisory Group of Experts (SAGE) on Immunization conducted a review of the NSEs of BCG and 
concluded that BCG was associated with reductions of overall mortality, that was not explained by prevention of 
TB; recommending further research into the NSEs of BCG9.
The immunological mechanisms underlying the potential NSEs of BCG were also reviewed by SAGE; the avail-
able studies were too heterogeneous to provide conclusive evidence10. It has been proposed that cross-protection 
mediated by heterologous T cell memory activation could be one of the underlying mechanisms11. Furthermore, 
recently BCG was found to induce epigenetic reprogramming of monocytes in adults, causing increased cytokine 
release in response to nonrelated pathogens, or so-called ‘trained innate immunity’12,13. Finally, BCG was found to 
1Department of Pediatrics, Copenhagen University Hospital, Hvidovre, Kettegårds Allé 30, 2650, Hvidovre, 
Denmark. 2The Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, 
Blegdamsvej 9, 2100, Copenhagen, Denmark. 3Department of Infectious diseases, Copenhagen University Hospital, 
Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark. 4Department of Pediatrics, Kolding Hospital, 
Sygehusvej 24, 6000, Kolding, Denmark. 5Research Center for Vitamins and Vaccines (CVIVA), Bandim Health 
Project, Statens Serum Institut, Artillerivej 5, 2300, Copenhagen, Denmark. 6Department of Internal Medicine 
and Radboud Center for Infectious Diseases, Radboud University Medical Center, Geert Grooteplein 8, 6525 GA, 
Nijmegen, The Netherlands. Correspondence and requests for materials should be addressed to N.M.B. (email: 
ninabirk@dadlnet.dk)
Received: 23 May 2017
Accepted: 25 August 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIeNTIfIC RepoRts | 7: 12398  | DOI:10.1038/s41598-017-11601-6
induce a nonspecific response to non-mycobacterial infections mediated by heterologous Th1/Th17 responses14, 
representing yet another potential biological mechanism which could explain NSEs.
Within a randomized clinical trial of neonatal BCG in Danish children, we aimed to evaluate effects of BCG 
within the adaptive immune system by assessing the distribution of T and B lymphocyte subsets in peripheral 
blood 4 days post-randomization, and 3, and 13 months of age
Materials and Methods
Setting. The present study was nested within The Danish Calmette Study, a multicenter, randomized clinical 
trial with 1:1 allocation of newborn infants to receive either BCG vaccination or no intervention within 7 days 
of birth15. Randomization was done using a centralized on-line system with stratification according to GA of the 
child (<37 weeks vs. ≥37 weeks). The allocation sequence was computer generated in permuting blocks of 2:4:6. 
Between October 2012 and December 2013 a total number of 4,262 newborns were randomized. The inclusion 
criteria were gestational age ≥32 weeks and a birth weight ≥1000 grams. Exclusion criteria were maternal intake 
of immune modulating medicine during pregnancy or signs of severe illness, or major malformation in the new-
born. Immediately following randomization the intervention group was vaccinated intra-dermally with BCG 
vaccine, SSI© strain 1331, in the standard dose of 0.05 ml in the upper, lateral part of the left shoulder. Design and 
methods have been described in detail elsewhere16. No placebo was used, since it is not possible to mimic the pus-
tule at the infants arm following a BCG vaccination, hence parents were not blinded to the intervention. However, 
the study staff was blind to the intervention at data collection by covering the site of a potential scar at the clinical 
examinations by a plaster and blood samples were given anonymized study id numbers.
Inclusion into the present study. Parents giving birth at Copenhagen University Hospital, Hvidovre, who 
had already provided consent for participating in the Danish Calmette Study within the inclusion period from 
June 2013 to December 2013, were prior to randomization invited to participate in this immunological substudy 
(Fig. 1). Infants, who were randomized on days which were compatible with later blood sampling, were invited to 
participate. Unfortunately, we collected no data on refusals.
Background information and clinical follow-up. Background information was collected by a structured 
telephone interview conducted in the third trimester of pregnancy. At 3 and 13 months of age all infants were 
invited for a clinical examination at the hospital preceded by a follow up telephone interview.
Figure 1. Flowchart of infants included into the study assessing the effect of BCG on T and B cell subsets by 
flow cytometry. A total of 601 infants were randomized within the Danish Calmette study in the inclusion 
period of the present substudy. Overall 118 infants participated in the present study; 114 infants were enrolled at 
day 4, further 2 infants were enrolled at 3 and 13 months.
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Blood samples and flow cytometry. To assess T and B cell subsets, blood samples were collected at three 
time points: at 4 (±2) days post randomization, and at 3 months and 13 months of age.
Flow cytometry to determine lymphocyte subsets was done using peripheral blood collected in 2 mL EDTA 
tubes. Gating strategies are shown in Figs 2 and 3. In brief, 100 µL of EDTA blood was incubated with fluores-
cent dye–conjugated monoclonal antibodies at room temperature for 20 minutes according to the manufactur-
er’s instructions. Erythrocytes were then lysed with 2 ml of Lysing Solution (Becton Dickinson (BD), Franklin 
Lakes, NJ, USA) at room temperature for 20 minutes, where after the samples were washed and re-suspended in 
FACS Flow (BD). Monoclonal antibodies used were 1-phycoerythrin (PE), peridinin chlorophyll proteins–cya-
nine (PerCP-Cy5.5), 1-fluorescein isothiocyanate (FITC), 1-allophycocyanin (APC), 1-phycoerythrin combined 
with cyanine dye Cy7 (PE-CY7), and 1-allophycocyanin combined with an analog of Cy7 (APC-H7) for iso-
type controls. To determine specific cell subsets CD28-PE, CCR7-PE, CD25-PE, CD161-PE, CD8-PerCPCy5.5, 
CD24- PerCPCy5.5, CD95-FITCH, CD31- FITCH, CD127- FITCH, HLADR-APC, CD45RA- APC, CD3- APC, 
CD27-PE-Cy7, CCR6-PE-Cy7, CD38- PE-Cy7, CD4-APC-H7, and CD19-APC-H7 were used, all purchased 
from BD.
Acquisition was done using a 6-color FACS Canto (BD), and data were processed using FACS Diva software 
(BD). A minimum of 100,000 cells were acquired in each sample. All lymphocyte gating was conducted by one 
examiner (NMB) blinded to the intervention group. Lymphocyte subsets are given as proportions (%)of the 
parent cell population concerned (CD4+ T cells, CD8+ T cells, or CD19+ B cells) as well as absolute cell counts 
(cells/µl) (Table 1). Geometric means are given in Supplementary Table A. Absolute cell counts were calculated 
by multiplying proportion of cells by total lymphocyte count (cells/µl) obtained from a differential count (Sysmex 
XE-5000, Sysmex, Mundelein, IL, USA) analyzed at the Department of Clinical Biochemistry, Copenhagen 
University Hospital, Hvidovre.
Outcomes. The predefined primary outcome was proportions of T and B lymphocyte subsets 4 days post 
randomization. The secondary outcomes were the cell subsets measured as absolute counts at 4 (±2) days post 
randomization, and 3 and 13 months and as proportions at 3 and 13 months. The cell subsets were grouped into 
the following categories:
Immature T cells and thymic output. Recent thymic emigrants (RTE) ((CD4+/CD8+) CD45RA+CD31+) and 
Naive cells ((CD4+/CD8+) CD45RA+CD27+CCR7+)17,18.
Figure 2. Gating strategy. Representative plots illustrating gating strategies within the CD4+ and CD8+ T 
cell compartment of (A, B) Recent thymic emigrants (CD45RA+CD31+), (C, D) Late differentiated cells 
(CD45RA+CD27-CCR7-), (E, I) Effector memory cells (CD45RA-CD27+CCR7-), (F, J) Central memory cells 
(CD45RA-CD27+CCR7+) (G, H) Naïve cells (CD45RA+CD27+CCR7+) including relevant isotype control.
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Immune regulation. Regulatory T cells (Tregs) (CD3+CD4+CD25+CD127low)19, B cells with the phe-
notype of CD19+CD24highCD38high 20, Th17 cells (CD3+CD4+CCR6+CD161+)21,22, and Tc17 cells 
(CD3+CD8+CCR6+CD161high)23,24.
The B cell phenotype CD19+CD24highCD38high has been shown to be enriched for IL-10 producing cells and 
to have regulatory capacity20. Due to the lack of IL-10 measurements in this study, this cell type will be referred 
to by its phenotype.
T cell homeostasis. Central memory cells ((CD4+/CD8+) CD45RA−CD27+CCR7+), Effector memory cells 
((CD4+/CD8+) (CD45RA−CD27+CCR7−), Late differentiated cells ((CD4+/CD8+) CD45RA+CD27−CCR7−), 
Chronic activated cells ((CD4+/CD8+) HLADR+CD38+), and Apoptotic cells ((CD4+/CD8+) CD95+CD28−)18.
Sample size. The sample size was based on previous work with T cell subsets where the mean of recent 
thymic emigrants (RTE) in adults was 24.1 (SD 10.1). To detect a difference of 30% between groups, we needed 
to include 43 in each group (2-sided test, power 90%, alpha 0.05). To account for dropouts, we aimed to include 
a minimum of 100 infants.
Statistical methods. As data were not consistently log-normally distributed, bootstrapped sampling with con-
fidence intervals as the 2.5% and 97.5% percentiles was conducted, but showed no difference from the standard 
normal-based confidence interval (CI); hence the latter will be shown. All infants in this substudy followed allocation.
The primary estimate of the BCG effect is presented as the geometric mean ratio (GMR) with 95% CI obtained 
as the anti-logged coefficient from a linear regression with the log-concentration or log-proportion as outcome 
and randomization group as covariate.
On the basis of previous findings of BCG having more pronounced beneficial non-specific effects in girls25 we 
pre-specified that primary outcome estimates would be assessed both overall and stratified by sex.
The following predefined potential effect modifiers were assessed: age at randomization (which was specified 
as 0–1 day versus 2–7 days, since most children were included during the first days of life and further grouping 
would result in small group sizes and limited power) and maternal BCG (yes/no).
To assess changes in each cell subpopulation over time (4 days, 3 months, 13 months) the hypothesis of equal 
BCG-effect over time (no time-interaction) was tested in a model with BCG, time, and the interaction BCG*time, 
leaving the correlation structure unspecified.
To test a potential effect of BCG within groups of subsets according to their function: “Immature T cells and 
thymic output”, “Immune regulation”, and “T cell homeostasis” post-hoc analysis comparing total effect within 
each group were performed. We accounted for potential correlation between the cell subsets by using the clus-
tered variance estimator.
Figure 3. Gating strategy of phenotypes of T and B cells assessed in infants randomized to BCG or no BCG at 
birth. Representative plots illustrating gating strategies within the CD19 + B cell compartment (1) and CD4+ 
and CD8+ T cell compartments (1 and 2) of (A) T regulatory cells (CD3 + CD4 + CD25 + CD127low), 
(B) CD19 + CD24high + CD38high, (C) TC 17 cells (CD3 + CD8 + CCR6 + CD161high), (D) TH 17 cells 
(CD3+CD4 + CCR6 + CD161+), (E,F) Chronically activated cells (HLADR + CD38+), (G,H) Apoptotic 
cells (CD95 + CD28−), including relevant isotype control.
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Since we have no data on which infants that were invited into this substudy but refused to participate, a com-
parison was made between baseline characteristics in infants included into the present study and infants included 
at Copenhagen University Hospital, Hvidovre in the inclusion period.
Data were analyzed according to a predefined statistical analysis plan which was deposited at the Data 
and Safety Monitoring Board before unblinding the study; post-hoc analyses were clearly stated as such. A 
5%-significance level was used. All analyses were performed using STATA 13.1 (StataCorp LP, College Station, 
Texas, USA).
Ethical considerations. This study was approved by the Committees on Biomedical Research Ethics (J.no. 
H-3–2010–087), the Danish Data Protection Board (J.no. 2009-41-4141), and the Danish Medicines Agency 
(J.no.2612-4356.EudraCT 2010-021979-85. Protocol 2009-323).
The study was registered September 22, 2012 at http://www.clinicaltrials.gov/ with registration number 
NCT01694108. The trial was supervised by the Good Clinical Practice Units of the Capital Region, Denmark and 
monitored by an independent Data and Safety Monitoring board. All methods were performed according to the 
Helsinki declaration and infants were included after oral and written informed consent from both parents.
Data availability statement. Use of data will be confined to the study group, but potential collaborators or 
request for data can be submitted to the corresponding author.
Results
During the inclusion period into the present study, a total of 601 infants were randomized at Copenhagen 
University Hospital, Hvidovre. Among these, 118 infants were included into this sub study and 483 infants were 
not. Of the 118 infants included, 56 were randomized to BCG and 62 to no intervention. Blood samples were 
collected from 114 infants at 4 days post randomization, 106 infants at 3 months, and 106 infants at 13 months 
(Fig. 1). The two groups had similar baseline characteristics (Table 2). There were only few drop-outs. However, 
the adherence was greater in the BCG group, the proportion of drop-outs being 4% (n = 2) in the BCG group 
4 days 3 months 13 months
Proportions (%)
Absolute cell counts 
(cells/µL) Proportions (%)
Absolute cell counts 
(cells/µL) Proportions (%)
Absolute cell counts 
(cells/µL)
GMRa (95% CI) GMR (95% CI) GMR (95% CI) GMR (95% CI) GMR (95% CI) GMR (95% CI)
BCG vs. no BCG p value BCG vs. no BCG p value BCG vs. no BCG p value BCG vs. no BCG p value BCG vs. no BCG p value BCG vs. no BCG p value
CD 4+ T cell subsets
CD4+ T cells 1.18 (0.94–1.49) 0.16 1.01 (0.89–1.14) 0.91 0.94 (0.78–1.13) 0.49
Naive cells 0.99 (0.98–1.02) 0.99 1.18 (0.93–1.50) 0.18 0.95 (0.97–0.99) 0.01 0.99 (0.87–1.13) 0.89 0.99 (0.97–1.01) 0.16 0.94 (0.78–1.13) 0.51
Recent thymic emmigrants 1.03 (0.96–1.11) 0.40 1.21 (0.94–1.55) 0.13 1.03 (0.97–1.08) 0.37 1.04 (0.90–1.19) 0.61 1.01 (0.95–1.07) 0.85 0.96 (0.79–1.17) 0.68
Tregs 1.05 (0.92–1.20) 0.46 1.28 (0.97–1.67) 0.08 1.00 (0.93–1.09) 0.92 0.93 (0.73–1.18) 0.53 1.04 (0.96–1.12) 0.59 0.98 (0.83–1.16) 0.84
Th 17 cells 1.17 (0.91–1.50) 0.22 1.30 (0.92–1.82) 0.13 1.13 (0.98–1.31) 0.10 1.02 (0.81–1.29) 0.84 1.05 (0.92–1.20) 0.49 0.99 (0.84–1.17) 0.92
Central memory cells 1.14 (0.75–1.73) 0.53 1.29 (0.80–2.07) 0.29 1.22 (0.84–1.77) 0.30 1.24 (0.85–1.83) 0.28 1.10 (0.96–1.85) 0.09 1.26 (0.89–1.78) 0.19
Effector memory cells 1.23 (0.85–1.77) 0.27 1.35 (0.90–2.02) 0.15 1.62 (1.20–2.21) 0.002 1.64 (1.21–2.23) 0.002 0.91 (0.70–1.20) 0.51 0.87 (0.67–1.13) 0.29
Late differentiated cells 1.01 (0.74–1.38) 0.95 1.18 (0.85–1.67) 0.31c 1.06 (0.74–1.52) 0.76 1.06 (0.74–1.52) 0.77 0.62 (0.38–1.00) 0.05 0.59 (0.38–0.93) 0.02
Chronic activated cells 1.16 (0.91–1.48) 0.23 1.38 (0.97–1.95) 0.07 0.86 (0.63–1.17) 0.33 0.85 (0.62–1.18) 0.33 0.86 (0.61–1.20) 0.37 0.85 (0.62–1.18) 0.33
Apoptotic cells 1.03 (0.82–1.30) 0.80 1.21 (0.87–1.68) 0.25 0.89 (0.68–1.18) 0.42 0.89 (0.68–1.16) 0.39 0.55 (0.32–0.92) 0.03 0.53 (0.31–0.91) 0.02
CD8+ T cell subsets
CD8+ T cells 1.08 (0.83–1.42) 0.55 0.90 (0.77–1.06) 0.21 0.89 (0.74–1.07) 0.21
Naive cells 0.99 (0.97–1.01) 0.29 1.06 (0.80–1.39) 0.70 0.98 (0.90–1.06) 0.56 0.88 (0.76–1.03) 0.11 1.06 (0.97–1.16) 0.18 0.93 (0.77–1.12) 0.45
Recent thymic emmigrants 0.99 (0.98–1.00) 0.36 1.06 (0.81–1.39) 0.68 1.00 (0.95–1.05) 0.95 0.91 (0.78–1.05) 0.20 1.03 (0.98–1.09) 0.23 0.91 (0.76–1.08) 0.28
Tc 17 cells 0.93 (0.74–1.17) 0.56 0.93 (0.67–1.29) 0.67 0.91 (0.74–1.13) 0.40 0.73 (0.50–1.07) 0.11 1.03 (0.82–1.28) 0.81 0.93 (0.74–1.18) 0.54
Central memory cells 0.94 (0.70–1.27) 0.67 0.97 (0.67–1.40) 0.86 1.15 (0.87–1.53) 0.33 1.00 (0.71–1.42) 0.99 1.30 (0.94–1.81) 0.11 1.11 (0.75–1.64) 0.59
Effector memory cells 0.98 (0.66–1.45) 0.91 0.99 (0.61–1.59) 0.95 1.69 (1.06–2.70) 0.03 1.41 (0.83–2.41) 0.20 0.99 (0.68–1.45) 0.97 0.85 (0.56–1.29) 0.43
Late differentiated cells 0.91 (0.62–1.34) 0.63 0.91 (0.58–1.43) 0.69 0.96 (0.55–1.70) 0.90 0.84 (0.45–1.55) 0.57 0.59 (0.29–1.18) 0.14 0.53 (0.25–1.11) 0.09
Chronic activated cells 1.07 (0.78–1.48) 0.66 1.25 (0.81–1.92) 0.32 0.82 (0.57–1.17) 0.27 0.72 (0.47–1.12) 0.14 0.90 (0.66–1.21) 0.48 0.80 (0.56–1.11) 0.17
Apoptotic cells 1.02 (0.82–1.26) 0.88 1.06 (0.76–1.48) 0.71 0.94 (0.65–1.37) 0.76 0.84 (0.54–1.32) 0.46 0.83 (0.61–1.12) 0.22 0.75 (0.52–1.09) 0.13
CD 19+ B cell subsets
CD19+ B cells 1.08 (0.84–1.41) 0.54 1.02 (0.87–1.19) 0.84 1.00 (0.84–1.19) 0.99
CD19+CD24high+CD38high 0.99 (0.96–1.02) 0.52 1.08 (0.83–1.42) 0.56 0.98 (0.86–1.12) 0.78 0.99 (0.81–1.20) 0.89 1.05 (0.93–1.19) 0.45 1.04 (0.84–1.28) 0.74
Table 1. Overall effects of neonatal BCG on lymphocyte subsets: immature cells and thymic 
output (Naïve T cells and recent thymic emigrants (RTE)), immune regulation (T regulatory cells 
(Tregs), CD19+CD24high+CD38high, Th 17 cells, Tc 17 cells), and T cell homeostasis (central memory T 
cells, effector memory T cells, late differentiated T cells, chronic activated cells and Apoptotic cells) assessed by 
flow cytometry. aGeometric mean ratio
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vs. 16% (n = 10) in the control group (p = 0.04) (Table 2). Though it was not an exclusion criterion, none of 
the participating families had preterm children. Hence, our study population consisted of term (born between 
gestational weeks 37 + 0 and 41 + 6) children only. We have no information on infants whose parents declined 
the invitation to participate in this substudy. However, there were no differences in background characteristics, 
comparing infants included in the present study with infants randomized at Copenhagen University Hospital, 
Hvidovre in the inclusion period, but not included in the substudy (Supplementary Table B).
Effect of BCG on T and B cell subsets at 4 days post-randomization. We found no differ-
ence between the BCG group and the control group on proportion of T or B lymphocyte subsets at 4 days 
post-randomization (Table 1).
Immature cells and thymic output - naïve T cells. At 3 months, BCG-vaccinated infants had lower 
proportion of naïve CD4+ T cells than controls with GMR of 0.95, 95% CI (0.97–0.99), p = 0.01. No effects were 
found on RTEs.
Memory cells: effector memory T cells (TEM) and late differentiated T cells. At age 3 months, we 
found proportions of TEM to be higher in the BCG group compared to controls for both CD4+ T cells (GMR 
1.62, 95% CI (1.20–2.21), p = 0.002) (Fig. 4A) and CD8+ T cells (GMR 1.69, (1.06–2.70), p = 0.03) (Table 1). 
Furthermore, absolute count of CD4+ TEM was higher in the BCG group (GMR 1.64, 95% CI (1.21–2.23), 
p = 0.002) (Table 1). This difference was not seen at 13 months.
At 13 months, BCG-vaccinated infants had fewer late differentiated CD4+ T cells compared to controls, both 
in proportions (GMR 0.62, 95% CI (0.38–1.00), p = 0.05) (Fig. 4B) and in absolute cell counts (GMR 0.59, 95% 
CI (0.38–0.93), p = 0.02) (Table 1).
Apoptotic T cells. At 13 months, BCG-vaccinated infants had lower proportion of apoptotic CD4+ T cells 
than controls (GMR 0.55, 95% CI (0.32–0.92), p = 0.03) (Fig. 4C). The same was found for absolute counts of 
apoptotic CD4+ T (GMR 0.53, 95% CI (0.31–0.91), p = 0.02) (Table 1).
Immune regulation. No overall effects were found on immune regulatory cells.
Effect modification by sex. A sex differential effect of BCG was seen in CD19+CD24highCD38high cells 
at the age of 13 months with a GMR 0.89, 95% CI (0.75–1.05) and 1.26, 95% CI (1.06–1.50) for boys and girls, 
respectively (p-value for interaction between BCG and sex = 0.005) (Fig. 4D). The same tendency was seen at 3 
months: GMR for boys: 0.86, 95% CI (0.72–1.04) and for girls: GMR 1.12, 95% CI (0.93–1.35), p-value for inter-
action = 0.05. No sex differential effect was found in the other cell subsets (data not shown).
Enrollment
BCG No BCG
p valuen = 56 n = 62
Age at randomizationa
0–1 days 32(57%) 41(66%) 0.32
2–7 days 24(43%) 21(34%)
Male sexa 29 (52%) 32 (52%) 0.99
Gestational age (weeks)b 40 (38–41) 40 (38–41) 0.85
Weight (kg)b 3.5 (3.0–4.0) 3.5 (2.8–4.0) 0.21
Caesarean sectiona 7 (13%) 15 (24%) 0.10
Maternal BCGa 13 (24%) 9 (15%) 0.21
Parental etnicity different from Danisha 8 (14%) 11 (18%) [1] 0.58
Maternal smoking during pregnancya 3(5%) 5 (8%) [1] 0.56
Level of maternal educationa [1] 0.56
Basic schooling and non-theoretical education 10 (18%) 14(23%)
Theoretical education incl BA level 28 (51%) 25(41%)
Master level or more 17 (31%) 22 (36%)
Siblingsa 19 (34%) 21 (34%) 0.99
Atopic predispositionC 39 (70%) 39(63%) 0.44
Lymphocytes (10^9/L) 4 days 5.5 5.3 0.43
Lymphocytes (10^9/L) 3 months 5.6 5.8 0.51
Lymphocytes (10^9/L) 13 months 5.7 6.0 0.40
Lost to follow-upa 2(4%) 10(16%) 0.04
Table 2. Background characteristics at baseline for infants randomized to BCG or no intervention in the 
assessment of T and B cell subsets. aNumber(Frequency) [missing]. bMedian (10–90 percentiles) [missing]. 
cAtopic disposition is defined as at least one first degree relative with atopic disease. Atopic disease is defined as 
physician-diagnosed atopic eczema, asthma, allergic rhinoconjunctivitis or food allergy.
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Effect modification by time of vaccination. At all three time points, BCG-vaccinated infants 
randomized at the age of 0–1 days (early) had higher proportion of Tregs compared to controls, whereas 
BCG-vaccinated infants randomized at age 2–7 days (late) had lower proportion of Tregs compared to controls 
(Table 3). At 4 days post randomization, there was a difference in the effect of BCG between children randomized 
early or late in the proportion of CD19+CD24highCD38high B cells; BCG was associated with a lower proportion 
in children vaccinated late. At 3 months of age, there was a difference in the effect of BCG between children 
randomized early or late in proportions of Th17 cells; BCG was associated with a higher proportion in children 
vaccinated late (Table 3).
No effect modification by ‘age at randomization’ was found in the other cell subsets and no effect modification 
was found for maternal BCG vaccination (data not shown).
Effect of BCG over time and in grouped analysis. No difference between randomizations groups within 
each cell subset was found over time (4 days, 3, and 13 months) and no difference between randomization groups 
within cells of “Immature T cells and thymic output”, “Immune regulation”, and “T cell homeostasis” was found in 
pooled analyses at 4 days, 3, and 13 months (data not shown).
Discussion
Here we present data from the largest randomized study conducted to determine the possible effects of neonatal 
BCG vaccination on T and B lymphocyte subsets in healthy infants. A total of 118 healthy infants were rand-
omized to neonatal BCG vaccination or to no intervention. No effect of BCG was found on the primary study 
outcome: proportions of any of the examined cell subsets 4 days post randomization. BCG was associated with 
higher proportions and absolute counts of both CD4+ T and CD8+ effector memory T cells at 3 months and 
reduced proportion and absolute counts of apoptotic and late differentiated cells at 13 months. In contrast, no 
overall difference was observed in naïve cells, RTEs, or cells affecting immune regulation. Finally, the association 
between BCG and cells of immune regulation (Tregs, Th17, and CD19+CD24highCD38high B cells) differed by age 
at vaccination. A sex differential effect of BCG was found on CD19+CD24highCD38high B cells. Thus, overall we 
found limited impact of neonatal BCG vaccination on T and B lymphocytes subsets; no clear pattern was identi-
fied that could theoretically explain non-specific beneficial effects of BCG.
Few previous studies investigated the effect of neonatal BCG in peripheral blood - ex vivo. In a study of 
103 neonates activated T cells (CD4+CD25+) and natural Tregs (CD4+ CD25+FOXP3+) were measured at 4.5 
months of age and compared between infants vaccinated at birth and BCG naïve infants, who were randomized 
to postponed BCG following blood sampling at 4.5 months26; they found no difference between groups. A ten-
dency towards reduced proportions of Tregs (FoxP3 + CD45RO + CD4+) assessed at age 2–3 months following 
neonatal BCG (mean BCG vs. no BCG was 9.1 vs. 11.6, p = 0.07) was however demonstrated in a study from 
the Philippines27. In contrast, in whole blood cultures, after antigen-specific stimulation, several effects of BCG 
have been described in infants; there amongst the induction of both a Th1 and a Th2 response26,28,29, a Th17 
response26,29, mycobacterial-specific polyfunctional CD4+ T cells (producing a combination of IFN-γ, interleukin 
(IL)-2, and tumor necrosis factor (TNF)-a)30–34, and Tregs26,35,36.
Our findings of no effect on RTEs, which are T cells recently generated in the thymus37, are in line with our 
findings with respect to BCG and thymic size; within the same study population BCG did not affect thymic size 
measured as thymic index by ultrasound38. This suggests that any effect of BCG is not mediated by affecting 
thymic size or thymic output.
In memory cell subsets, BCG vaccination resulted in higher proportion of CD4+ TEM cells at 3 months of age. 
Likewise, increases in both absolute counts of CD4+ TEM cells and in proportions of CD8+ TEM cells were seen. 
We speculate that these changes may represent induced T cell memory and hence specific effects of the vaccine. 
However, functional assays to determine antigen-specific alterations in T and B cell subpopulations were not 
performed, but may have provided important information. CD4+ TEM cells have been described to migrate to 
inflamed tissues following antigen exposure, where they display immediate effector functions. In contrast, central 
memory cells (TCM) home to T cell areas of secondary lymphoid organs, they are long-lived and show limited 
effector functions, but differentiate to effector cells upon antigen exposure39. Since CCR7− effector T cells (TEM) 
have been associated with persistent activation of T cells in e.g. chronic viral infections where the antigen is not 
cleared40–42 and in children with active TB43, Soares et al. suggest that their similar finding of TEM cells (CD45RA− 
CD27+CCR7−) to be the dominant phenotype 10 weeks following neonatal BCG, may reflect the persistence of 
BCG31. Our findings of an increase at 3 months of TEM with an identical phenotype corroborate these results. 
Furthermore, in our cohort, in case of suppurative lymphadenitis as an adverse reaction to BCG, the mean time 
for onset was 87 days (range 25–200) after vaccination, supporting an BCG induced immunologic reaction 3 
months post vaccination44. This persistence of BCG was hypothesized to drive differentiation predominantly into 
effector cells and prevent the differentiation into central memory cells and long lived memory31.
A tendency towards higher proportion of CD4+ TCM cells at 13 months was found in the BCG group com-
pared to controls. It could be speculated that this shift from an increase in TEM at 3 months to an increase in TCM 
at 13 months, may indicate the conversion of effector memory to central memory cells and thus potentially long 
lived memory. The function and differentiation between memory T cells may, however, be even more complex, 
underlined by previous findings in infants of BCG-specific CD4+ T cells with a central memory phenotype but 
with functional features of effector memory cells >10 weeks post vaccination34. Our study included no functional 
assays, and we are not able to elaborate on the functional features of the T memory cells. At 13 months, fewer late 
differentiated cells and apoptotic cells, measured as both proportions and absolute counts, were found in the BCG 
group compared to the control group. Of note, few cells of both late differentiated cells and apoptotic cells were 
found, and random variation may have affected the results.
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Figure 4. Effects of neonatal BCG on cell subsets reflecting T cell homeostasis and immune regulation. 
In the left column, dot plots illustrating % of CD 4+ effector memory cells, horizontal line representing 
the geometric mean (A), % of CD 4+ late differentiated cells (B), % of CD 4+ apoptotic cells (C), and 
CD19 + CD24high + CD38high cells (D) at 3 time points in BCG vaccinated infants and controls. The right 
column illustrates geometric mean ratio (GMR) of the cell phenotypes at all three time points (error bars depict 
95% confidence intervals) except for D which shows % of CD19 + CD24high + CD38high in females.
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No overall effects were found on any immune regulatory cell subset, and as such we found no clear indi-
cation of altered proportions or absolute counts of cells immune regulation after BCG vaccination at birth. 
However, in analyses of effect modification our results suggest that effects of BCG on regulatory cells (Tregs, 
CD19+CD24highCD38high cells, and Th17 cells) differ, depending on age of vaccination. In parallel, a similar find-
ing was done in another immunological substudy nested within the Danish Calmette Study, which assessed the 
effect of BCG on antibody response following routine vaccination45. Here, BCG was associated with higher levels 
of antibodies if given at day 2–7 versus at day 0–145. In the present study, BCG induced an increase in the pro-
portions of Tregs following early (0–1 days) BCG vaccination, whereas the opposite effect was seen after late 
(2–7 days) BCG. Hence, age of BCG vaccination may be important in the immune regulating capacity of BCG, 
and we speculate that an increase in proportions of Tregs, in part, may explain lower antibody production. The 
mechanism may be the ability of Tregs to suppress development of long-lived plasma cells, as recently described 
in mice46. Since regulatory T and B cells are thought to play an important role in both vaccine immunogenicity in 
early life47 and in development of autoimmune disease48, such time differential effects may be pursued in future 
studies.
Timing of sampling is important. Sampling 4 days post randomization was chosen to asses early effect of 
BCG, since a rapid beneficial effect of BCG on was seen on all-cause mortality in newborns within few days 
after vaccination in Guinea Bissau8. To assess the effect of BCG without any potential impact by other vaccines 
the 3-month-blood sample was scheduled before the first dose of the pentavalent vaccine (DiTeKiPol/Act-Hib) 
and the pneumococcal conjugate vaccine (Prevenar 13), which are recommended at 3, 5 and 12 months as part 
of the standard vaccination program in Denmark. The 13-month-blood sample was scheduled 4 weeks after the 
last dose DiTeKiPol/Act-Hib and Prevenar 13, since DiTeKiPol has been proposed to have detrimental NSEs49 on 
infants heath. Based on previous findings of a peak response to neonatal BCG at 6–10 weeks of age, where after 
it gradually waned50, and the fact that adaptive immunity takes weeks to develop, it could be argued, that 4 days 
post vaccination may be too premature to assess changes within the adaptive immune system. In contrast, it is not 
possible to rule out that 3 months may be too late to capture the peak in specific response. However, a tendency 
towards reduced proportions of Tregs with the phenotype FoxP3 + CD45RO + CD4+ as well as the induction of 
a Th 1 immune response were demonstrated after sampling at age 2–3 months following neonatal BCG27.
We observed a sex differential effect of BCG on CD19+CD24highCD38high cells, with higher propor-
tions in females and lower proportions in males compared to controls at 13 months. The proportions of 
CD19+CD24highCD38high cells in this study, however, were high (76% at 4 days post randomization), and it is 
likely that this phenotype includes other cells than IL-10 producing cells. Our results are in line with findings 
of sex differences in immune function and response to vaccination51,52 including BCG8,25, with females typically 
developing higher antibody responses to vaccines53.
The hypothesis that live vaccines have stronger beneficial NSEs in children born of mothers who were primed 
with the same vaccine was first invoked after finding that infants vaccinated with measles vaccine in the presence 
0–1 days GMa 2–7 days GM
0–1 days GMRb (95% 
CI)
2–7 days GMR (95% 
CI)
p valuecBCG
No 
BCG BCG
No 
BCG BCG vs no BCG BCG vs no BCG
Cell subsets (%) 4 days
26d 35 19 20
  Tregs 9.1 7.5 7.5 8.9 1.22 (1.03–1.43) 0.84 (0.68–1.03) 0.007
  TH 17 cells 0.6 0.6 0.9 0.6 1.01 (0.73–1.40) 1.42 (0.95–2.11) 0.19
  TC 17 cells 1.5 1.8 1.7 1.6 0.85 (0.63–1.15) 1.08 (0.74–1.55) 0.33
  CD19 + CD24high + CD38high 77 60 76 81 1.02 (0.98–1.06) 0.94 (0.89–0.99) 0.02
3 months
29 33 22 16
  Tregs 7.5 7.0 7.0 7.8 1.06 (0.96–1.18) 0.90 (0.79–1.02) 0.04
  TH 17 cells 1.5 1.5 1.6 1.2 1.02 (0.84–1.24) 1.40 (1.11–1.79) 0.04
  TC 17 cells 0.9 1.1 1.1 0.9 0.80 (0.61–1.05) 1.17 (0.84–1.63) 0.9
  CD19 + CD24high + CD38high 35 36 34 34 0.97 (0.81–1.15) 1.00 (0.81–1.23) 0.83
13 months
29 34 22 15
  Tregs 7.9 7.2 7.5 8.2 1.10 (1.00–1.22) 0.91 (0.80–1.04) 0.02
  TH 17 cells 2.3 2.2 2.5 2.1 1.05 (0.87–1.26) 1.15 (0.89–1.47) 0.56
  TC 17 cells 0.8 0.8 0.8 0.7 1.00 (0.76–1.33) 1.15 (0.80–1.69) 0.54
  CD19 + CD24high + CD38high 20 18 18 19 1.11 (0.95–1.30) 0.95 (0.77–1.17) 0.24
Table 3. Effect modification by age of randomization in the assessment of the effect of neonatal BCG at birth 
on T and B cel subsets.  The cell substes (given as proportions) included are cells affecting immune regulation (T 
regulatory cells (Tregs), TH 17 cells, TC 17 cells, and B cells with the phenotype of CD19 + CD24high + CD38high) 
stratified by “age of randomization”. aGeometric mean. bGeometric mean ratio. cp value for interaction. dn 
number (%).
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of maternal measles antibodies had a lower mortality than infants vaccinated in the presence of no maternal 
antibodies54. Maternal BCG status was therefore assessed within the Danish Calmette Study, and as hypothesized, 
a potential beneficial positive NSE of BCG was found on infectious disease episodes55 and hospitalizations for 
infectious diseases among children whose mothers were BCG-vaccinated, whereas no effect was seen in children 
of BCG-unvaccinated mothers (Stensballe et al., “BCG vaccination at birth and rate of hospitalization for infec-
tion until 15 months of age in Denmark. A randomized clinical multicenter trial”, submitted for publication). We 
found no effect modification by maternal BCG on T and B cell subsets, however only 20% of the mothers were 
BCG vaccinated, providing low power.
In a clinical perspective, no effect of BCG was found on the primary outcome of the Danish Calmette 
Study16: overall hospitalizations at 15 months of age (hazard ratio comparing BCG vs. no BCG of 1.05, 95% 
CI 0.93–1.18)15. Also, BCG did not affect parent-reported infections (incidence rate ratio comparing BCG vs. 
no BCG of 0.87, 95% CI 0.72–1.05 from 0–3 months and of 1.02, 95% CI: 0.97–1.07 from 3–13 months)55 or 
recurrent wheeze in the first year of life (relative risk comparing BCG vs. no BCG of 1.07, 95% CI 0.89–1.28)56. 
Furthermore, no effect of BCG on overall antibody response to the routine vaccines against DiTeKiPol/Act-Hib 
and Prevenar 13 at 13 months of age was found45; nor on in vitro cytokine responses to specific and non-specific 
stimulation (Nissen et al., Bacillus Calmette-Guérin vaccination at birth and in vitro cytokine responses to spe-
cific and non-specific stimulation. A randomized clinical trial, submitted for publication). However, BCG was 
found to protect against atopic dermatitis among newborns with atopic predisposition at 13 months (Thøstesen 
et al., Neonatal BCG-vaccination and atopic dermatitis before 13 months of age. A randomised clinical trial, sub-
mitted for publication). Taken together these findings suggest limited NSEs in a Danish cohort of infants. This is 
in agreement with the limited overall impact of neonatal BCG on T cells and T cell function within the first year 
of life in Danish children.
Strengths of this study are the randomized and prospective design with an overall follow-up rate of 90% and 
few drop-outs. The lack of intracellular staining of FOX-P3 (Forkhead Box P3) in the assessment of Tregs and 
the lack of IL-10 staining in the assessment of CD19+CD24highCD38high cells, which was not logistically feasible, 
represents weaknesses of this study. A limitation is that the recruitment was based on convenience sampling with 
the risk of selection bias. Functional assays may have provided important information. We did not adjust for 
multiple testing which imposes the risk of a type 1 error. However, due to the explorative nature of this study and 
based on adherence to a predefined statistical analysis plan, we chose to report data without adjusting for multiple 
testing and let the reader interpret the analysis as exploratory. However, the reader should keep the risk of type 1 
error in mind57.
In conclusion, limited impact of BCG vaccination at birth on lymphocyte subsets was found in healthy infants 
in a high-income setting within the first 13 months of life. Since no marked effect of BCG was found on clinical 
outcomes in our setting, it is not possible to rule out that BCG may affect lymphocyte subsets and lead to NSEs 
in other settings.
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